Phase 3 data presents strong case for switching from Humira to Janssen’s Tremfya in plaque psoriasis
September 13, 2018Research and Development Humira, Janssen, Tremfya, pharma, psoriasis
Janssen has unveiled new Phase 3 data derived from two separate trials on the efficacy and benefits of switching to …
Takeda set to move from Deerfield Illinois, 1000 jobs affected
September 12, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Jobs, Shire, Takeda, deerfield, illinois
Japanese multinational Takeda is set to shut down its US headquarters in Deerfield, Illinois following the final stages of its …
Teva names new President, TAPI and Biologics Operations
September 12, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Novartis, Teva, appointment
Israeli generic drug specialist Teva has announced its appointment of John Nason in a multi-faceted role as President of Teva …
Merck KGaA and Pfizer’s combo impresses in first-line treatment of advanced kidney cancer
September 12, 2018Research and Development, Sales and Marketing Cancer, Kidney cancer, Merck KGaA, Pfizer, pharma
Bavencio (avelumab), Merck KGaA and Pfizer’s human anti-programmed death ligand-1 (PD-L1) antibody, combined with the latter’s Inlyta (axitinib) has shown …
BMS’ investigational psoriasis drug hits primary endpoint in skin clearance at Phase 2
September 12, 2018Research and Development BMS, BMS-986165, Bristol-Myers Squibb, pharma, psoriasis
Bristol-Myers Squibb has unveiled new Phase 2 data for its investigational oral, selective tyrosine kinase 2 (TYK2) inhibitor, known as …
More effective flu vaccine could prevent hundreds of elderly deaths across UK this winter
September 12, 2018Medical Communications, Research and Development NHS, Vaccine, flu, influenza, pharma
Public Health England has revealed that an enhanced, “adjuvanted” vaccine is to be made available for over-65s this winter, and …
UK Health Secretary Matt Hancock rallies against ‘rip off’ pharma companies
September 11, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biogen, Matt Hancock, NICE, Vertex, pharma, pricing
British Health Secretary Matt Hancock has said that pharmaceutical companies are trying to “rip off taxpayers” and that big business …
Protesters in Manchester call on NICE to approve Biogen’s $750,000 drug Spinraza
September 11, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NICE, Spinraza, approval, protest, sma
Protesters in Manchester have called on the National Institute of Health and Care Excellence (NICE), to overturn their rejection of …
UK health improving but challenges of an ageing population remain, says PHE report
September 11, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NHS, Public Health England, UK, pharma
A new report from Public Health England (PHE) has illuminated the primary health concerns in UK society today, revealing the …
Novartis eyecare unit Alcon to set up new HQ in Geneva, Switzerland
September 11, 2018Manufacturing and Production Alcon, Novartis, eye care, pharma
Alcon, the eyecare unit of Novartis, is set to move to a new home next year, after its parent company …
PhRMA blames hospitals for rising drug prices, hospitals association responds
September 11, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Donald Trump, Drug pricing, PhRMA, hospitals, pharma
The American pharmaceutical industry trade lobby PhRMA has suggested that hospitals are to blame for high drug prices as the …
Purdue-owning Sackler family own second opioid drug maker, FT reveals
September 10, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing OxyContin, Purdue Pharma, opioid, opioid crisis, sackler
The billionaire Sackler family, the owners of OxyContin drugmaker Purdue Pharma, have been revealed to own a second opioid drug …
Novo Nordisk stockpiles 16 weeks’ worth of insulin in preparation for hard Brexit
September 10, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, Novo Nordisk, UK, brexit, insulin, pharma, stockpiles
Danish multinational Novo Nordisk has announced that they are increasing their stocks of insulin products to ensure that there are …
Drug safety: UK and EU post-Brexit
September 10, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EMA, EU, Europe, MHRA, UK, brexit, drug safety, pharmacovigilance
What does Brexit mean for drug safety in Europe and the United Kingdom? Louis Goss looks into Britain’s exit from …
BMS’ Opdivo fails to win over NICE as adjuvant melanoma therapy
September 10, 2018Sales and Marketing BMS, NHS, NICE, melanoma, opdivo, pharma
Bristol-Myers Squibb has failed to convince NICE to approve the use of its PD-1 inhibitor immunotherapy Opdivo (nivolumab) as an …
Keytruda scores ground-breaking European approval in lung cancer subgroup
September 10, 2018Sales and Marketing Cancer, EU, Europe, MSD, Merck, NSCLC, keytruda, lung cancer, pharma
Keytruda (pembrolizumab) has chalked up yet another approval for MSD, this time in Europe in combination with permextred and platinum-based …
GSK’s Nucala data insufficient for US COPD approval
September 10, 2018Sales and Marketing COPD, FDA, GSK, Nucala, US, pharma
GlaxoSmithKline has suffered a regulatory blow in the label expansion of its interleukin-5 (IL5) inhibitor Nucala (mepolizumab), with the FDA …
Akcea cuts 10% of staff following FDA rejection
September 10, 2018Manufacturing and Production, Sales and Marketing Akcea, FDA, Waylivra, pharma
Akcea Therapeutics has been hit hard by the FDA’s decision to reject its drug Waylivra (volanesorsen) for the treatment of …
NICE rejects Roche’s Ocrevus in primary progressive multiple sclerosis
September 10, 2018Sales and Marketing NICE, Ocrevus, Roche, UK, multiple sclerosis, pharma
Of the 100,000 MS patients in England, around one in eight have the primary progressive form (PPMS), which brings debilitating …
UK Government to invest £200m in IT and technology boost for NHS
September 7, 2018Medical Communications, Sales and Marketing AI, Matt Hancock, NHS, NHS expo, pharma
The UK Government has lifted the curtain on plans invest more than £200 million to leverage innovations in technology and …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
